| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3290168 | Gastroentérologie Clinique et Biologique | 2010 | 4 Pages |
Abstract
SummaryIncretin-based therapies have shown promise in the treatment of type 2 diabetes. Here we review our current understanding of TGR5 as a target to induce glucagon-like peptide-1 (GLP-1) secretion. These new observations suggest that TGR5 agonists may constitute a novel approach to treat type 2 diabetes, as well as complications of diabetes, such as non-alcoholic fatty liver disease.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
T.W. H. Pols, J. Auwerx, K. Schoonjans,